Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

William Townsend; Wolfgang Hiddemann; Christian Buske; Guillaume Cartron; David Cunningham; Martin J.S. Dyer; John G. Gribben; Elizabeth H. Phillips; Martin Dreyling; John F. Seymour; Andrew Grigg; Judith Trotman; Tong-Yu Lin; Xiao-Nan Hong; Dirk Kingbiel; Tina G. Nielsen; Andrea Knapp; Michael Herold; Robert Marcus

doi:10.1097/hs9.0000000000000919

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tong-Yu Lin, Xiao-Nan Hong, Dirk Kingbiel, Tina G. Nielsen, Andrea Knapp, Michael Herold, Robert Marcus

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	HemaSphere
DOIs	https://doi.org/10.1097/hs9.0000000000000919
Publication status	Published - Jul 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/hs9.0000000000000919

Cite this

Townsend, W., Hiddemann, W., Buske, C., Cartron, G., Cunningham, D., Dyer, M. J. S., Gribben, J. G., Phillips, E. H., Dreyling, M., Seymour, J. F., Grigg, A., Trotman, J., Lin, T.-Y., Hong, X.-N., Kingbiel, D., Nielsen, T. G., Knapp, A., Herold, M., & Marcus, R. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. https://doi.org/10.1097/hs9.0000000000000919

@article{de6d8873af2e4bf2a6075cbf2497ca90,

title = "Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study",

author = "William Townsend and Wolfgang Hiddemann and Christian Buske and Guillaume Cartron and David Cunningham and Dyer, {Martin J.S.} and Gribben, {John G.} and Phillips, {Elizabeth H.} and Martin Dreyling and Seymour, {John F.} and Andrew Grigg and Judith Trotman and Tong-Yu Lin and Xiao-Nan Hong and Dirk Kingbiel and Nielsen, {Tina G.} and Andrea Knapp and Michael Herold and Robert Marcus",

year = "2023",

month = jul,

doi = "10.1097/hs9.0000000000000919",

language = "English",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Lippincott Williams & Wilkins",

}

Townsend, W, Hiddemann, W, Buske, C, Cartron, G, Cunningham, D, Dyer, MJS, Gribben, JG, Phillips, EH, Dreyling, M, Seymour, JF, Grigg, A, Trotman, J, Lin, T-Y, Hong, X-N, Kingbiel, D, Nielsen, TG, Knapp, A, Herold, M & Marcus, R 2023, 'Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study', HemaSphere. https://doi.org/10.1097/hs9.0000000000000919

TY - JOUR

T1 - Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

AU - Townsend, William

AU - Hiddemann, Wolfgang

AU - Buske, Christian

AU - Cartron, Guillaume

AU - Cunningham, David

AU - Dyer, Martin J.S.

AU - Gribben, John G.

AU - Phillips, Elizabeth H.

AU - Dreyling, Martin

AU - Seymour, John F.

AU - Grigg, Andrew

AU - Trotman, Judith

AU - Lin, Tong-Yu

AU - Hong, Xiao-Nan

AU - Kingbiel, Dirk

AU - Nielsen, Tina G.

AU - Knapp, Andrea

AU - Herold, Michael

AU - Marcus, Robert

PY - 2023/7

Y1 - 2023/7

UR - http://dx.doi.org/10.1097/hs9.0000000000000919

U2 - 10.1097/hs9.0000000000000919

DO - 10.1097/hs9.0000000000000919

M3 - Article

SN - 2572-9241

JO - HemaSphere

JF - HemaSphere

ER -

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

UN SDGs

Access to Document

Other files and links

Cite this